Atovaquone in the treatment of Babesia microti infections in hamsters

Murray Wittner, Jeffrey Lederman, Herbert B. Tanowitz, Gary S. Rosenbaum, Louis M. Weiss

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The traditional therapy for the treatment of human Babesia microti infections has been the combination of clindamycin and quinine. However, in recent years, it has become apparent that some patients have not responded to this regimen. We became involved in the treatment of several cases of babesiosis in which atovaquone was used to treat this infection. Therefore, using the hamster model, we determined the efficacy of atovaquone alone as well as atovaquone plus azithromycin for the treatment of experimental babesiosis. Atovaquone (100 mg/kg/day) and atovaquone (100 mg/kg/day) with azithromycin (150 mg/kg/day) were effective agents for the treatment of experimental babesiosis in hamsters. When atovaquone was used as monotherapy recrudescences occurred. Organisms obtained from recrudescent animals, when inoculated into uninfected animals, proved to be unresponsive to atovaquone therapy, suggesting the emergence of drug resistance. Resistant organisms did not emerge in hamsters treated with the combination of atovaquone and azithromycin. Atovaquone should he considered in the therapeutic regimen of patients with babesiosis who have either failed standard therapy or have become intolerant to such therapy.

Original languageEnglish (US)
Pages (from-to)219-222
Number of pages4
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume55
Issue number2
StatePublished - 1996

Fingerprint

Babesia microti
Atovaquone
Cricetinae
Babesiosis
Infection
Azithromycin
Therapeutics
Quinine
Clindamycin
Drug Resistance

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Cite this

Atovaquone in the treatment of Babesia microti infections in hamsters. / Wittner, Murray; Lederman, Jeffrey; Tanowitz, Herbert B.; Rosenbaum, Gary S.; Weiss, Louis M.

In: American Journal of Tropical Medicine and Hygiene, Vol. 55, No. 2, 1996, p. 219-222.

Research output: Contribution to journalArticle

Wittner, M, Lederman, J, Tanowitz, HB, Rosenbaum, GS & Weiss, LM 1996, 'Atovaquone in the treatment of Babesia microti infections in hamsters', American Journal of Tropical Medicine and Hygiene, vol. 55, no. 2, pp. 219-222.
Wittner, Murray ; Lederman, Jeffrey ; Tanowitz, Herbert B. ; Rosenbaum, Gary S. ; Weiss, Louis M. / Atovaquone in the treatment of Babesia microti infections in hamsters. In: American Journal of Tropical Medicine and Hygiene. 1996 ; Vol. 55, No. 2. pp. 219-222.
@article{9640bab185e24d7099ef6a2d09f1757b,
title = "Atovaquone in the treatment of Babesia microti infections in hamsters",
abstract = "The traditional therapy for the treatment of human Babesia microti infections has been the combination of clindamycin and quinine. However, in recent years, it has become apparent that some patients have not responded to this regimen. We became involved in the treatment of several cases of babesiosis in which atovaquone was used to treat this infection. Therefore, using the hamster model, we determined the efficacy of atovaquone alone as well as atovaquone plus azithromycin for the treatment of experimental babesiosis. Atovaquone (100 mg/kg/day) and atovaquone (100 mg/kg/day) with azithromycin (150 mg/kg/day) were effective agents for the treatment of experimental babesiosis in hamsters. When atovaquone was used as monotherapy recrudescences occurred. Organisms obtained from recrudescent animals, when inoculated into uninfected animals, proved to be unresponsive to atovaquone therapy, suggesting the emergence of drug resistance. Resistant organisms did not emerge in hamsters treated with the combination of atovaquone and azithromycin. Atovaquone should he considered in the therapeutic regimen of patients with babesiosis who have either failed standard therapy or have become intolerant to such therapy.",
author = "Murray Wittner and Jeffrey Lederman and Tanowitz, {Herbert B.} and Rosenbaum, {Gary S.} and Weiss, {Louis M.}",
year = "1996",
language = "English (US)",
volume = "55",
pages = "219--222",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "2",

}

TY - JOUR

T1 - Atovaquone in the treatment of Babesia microti infections in hamsters

AU - Wittner, Murray

AU - Lederman, Jeffrey

AU - Tanowitz, Herbert B.

AU - Rosenbaum, Gary S.

AU - Weiss, Louis M.

PY - 1996

Y1 - 1996

N2 - The traditional therapy for the treatment of human Babesia microti infections has been the combination of clindamycin and quinine. However, in recent years, it has become apparent that some patients have not responded to this regimen. We became involved in the treatment of several cases of babesiosis in which atovaquone was used to treat this infection. Therefore, using the hamster model, we determined the efficacy of atovaquone alone as well as atovaquone plus azithromycin for the treatment of experimental babesiosis. Atovaquone (100 mg/kg/day) and atovaquone (100 mg/kg/day) with azithromycin (150 mg/kg/day) were effective agents for the treatment of experimental babesiosis in hamsters. When atovaquone was used as monotherapy recrudescences occurred. Organisms obtained from recrudescent animals, when inoculated into uninfected animals, proved to be unresponsive to atovaquone therapy, suggesting the emergence of drug resistance. Resistant organisms did not emerge in hamsters treated with the combination of atovaquone and azithromycin. Atovaquone should he considered in the therapeutic regimen of patients with babesiosis who have either failed standard therapy or have become intolerant to such therapy.

AB - The traditional therapy for the treatment of human Babesia microti infections has been the combination of clindamycin and quinine. However, in recent years, it has become apparent that some patients have not responded to this regimen. We became involved in the treatment of several cases of babesiosis in which atovaquone was used to treat this infection. Therefore, using the hamster model, we determined the efficacy of atovaquone alone as well as atovaquone plus azithromycin for the treatment of experimental babesiosis. Atovaquone (100 mg/kg/day) and atovaquone (100 mg/kg/day) with azithromycin (150 mg/kg/day) were effective agents for the treatment of experimental babesiosis in hamsters. When atovaquone was used as monotherapy recrudescences occurred. Organisms obtained from recrudescent animals, when inoculated into uninfected animals, proved to be unresponsive to atovaquone therapy, suggesting the emergence of drug resistance. Resistant organisms did not emerge in hamsters treated with the combination of atovaquone and azithromycin. Atovaquone should he considered in the therapeutic regimen of patients with babesiosis who have either failed standard therapy or have become intolerant to such therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029756593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029756593&partnerID=8YFLogxK

M3 - Article

C2 - 8780464

AN - SCOPUS:0029756593

VL - 55

SP - 219

EP - 222

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 2

ER -